Unknown

Dataset Information

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.


ABSTRACT:

Purpose

To characterize the safety, pharmacodynamics, and pharmacokinetics (PK) of vericiguat in healthy males.

Methods

Six phase I studies were conducted in European, Chinese, and Japanese males. Subjects received oral vericiguat as a single dose (0.5-15.0 mg solution [for first-in-human study] or 1.25-10.0 mg immediate release [IR tablets]) or multiple doses (1.25-10.0 mg IR tablets once daily [QD] or 5.0 mg IR tablets twice daily for 7 consecutive days). Bioavailability and food effects on vericiguat PK (IR tablets) were also studied in European subjects.

Results

Overall, 255 of 265 randomized subjects completed their respective studies. There were no deaths or serious adverse events. Vericiguat was generally well tolerated at doses ≤ 10.0 mg. In the first-in-human

SUBMITTER: Boettcher M 

PROVIDER: S-EPMC7935833 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature